Credits: Canva
An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.
One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.
Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.
The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.
The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.
Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”
The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.
Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.
The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.
Credit: iStock
Measles, a highly contagious but vaccine-preventable disease, has claimed another young life. Wisconsin has reported its first measles-related death since 1990, taking the reported US death toll to eight in 2026.
The US, which eliminated sustained domestic measles transmission in 2000, is witnessing a major resurgence. The Centers for Disease Control and Prevention (CDC) reported 4,852 confirmed measles cases as of October 29.
According to state health department reports, the country has recorded eight measles-related deaths this year: six in Pennsylvania, one in New York and one in Wisconsin. At least four involved children or infants.
However, the CDC has not yet updated its website and has confirmed only four measles-associated deaths so far this year.
Childhood vaccination rates have declined in recent years, falling below the 95% coverage generally needed to prevent outbreaks.
Disruptions to routine childhood immunisation during the COVID-19 pandemic, declining vaccination coverage and growing vaccine hesitancy have contributed to the resurgence. Vaccine scepticism has also been amplified by anti-vaccine messaging from the Donald Trump-led administration, including Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.
Also read: Pennsylvania Reports Sixth Measles Death As Outbreak Crosses 1,400 Cases Across 45 Counties
The Wisconsin Department of Health Services (DHS) reported the death of an infant due to measles, marking the state's first such death since 1990.
The coroner listed measles as the immediate cause of death, according to the official statement. DHS said it would not release additional information to protect the privacy of the child and family.
"It is with a heavy heart we are reporting the first death of an infant connected with a measles outbreak in Wisconsin in many years. My heart is broken for the family," said DHS Secretary Kirsten Johnson.
"Any death of a child is a tragedy and even more so when it is related to a vaccine-preventable disease. Measles can cause serious illness and death, and all Wisconsinites need to evaluate their risk and take steps to protect themselves and their family."
As of November 3, Wisconsin had reported 431 measles cases across 13 counties in 2026, the highest number recorded in the state in more than 35 years. Nine people have required hospitalisation due to severe symptoms.
Reported case counts may not reflect the full extent of transmission. Not everyone who develops symptoms seeks medical care or undergoes testing, meaning some infections may go unreported.
Declining childhood vaccination coverage is a major concern. US vaccination rates have fallen below the 95% coverage generally needed to prevent measles outbreaks.
Children younger than five years, pregnant people and those with weakened immune systems are at increased risk of severe complications.
Two doses of the measles, mumps and rubella (MMR) vaccine are approximately 97% effective against measles. Children as young as six months may receive an early dose in certain circumstances, including travel to areas experiencing outbreaks. This early dose does not replace the two routine doses recommended later in childhood.
Measles spreads through the air when an infected person coughs or sneezes. The virus can remain infectious in the air or on surfaces for up to two hours.
Initial symptoms include:
A rash usually develops several days later, beginning on the face and spreading down the body.
Although many people recover, measles can cause serious and potentially life-threatening complications, including pneumonia and encephalitis, or inflammation of the brain. The infection can also weaken the immune system, increasing vulnerability to other infections.
Credit: iStock
The sudden collapse and death of a nine-year-old girl inside her Delhi classroom following a cardiac arrest has raised concerns about sudden cardiac emergencies in children. The Class 3 student reportedly collapsed shortly after returning to the classroom from a games period.
CCTV footage showed her entering the classroom, holding her waist and falling to the floor. A teacher rushed to help her, while school staff took her to a nearby hospital. She was subsequently taken to another hospital in Nirman Vihar, where doctors declared her dead.
Speaking to HealthandMe, Dr Neeraj Awasthy, Senior Director, Pediatric Cardiology, Fortis Hospital, Okhla, said the heart condition in children are extremely rare and differ from those in adults.
"In adults, a heart attack is usually caused by a blockage in the arteries supplying the heart. In children, sudden cardiac arrest is more often associated with an underlying heart condition, such as a structural abnormality, an inherited problem affecting the heart rhythm or inflammation of the heart muscle," he said.
According to Dr Awasthy, sudden cardiac arrest in children is commonly associated with structural heart abnormalities, inherited rhythm disorders and inflammation of the heart muscle.
In a post on X, Dr Sudhir Kumar, Neurologist at Apollo Hospitals, Hyderabad, identified other conditions that can trigger cardiac arrest in apparently healthy children:
Some children may have no symptoms until a life-threatening cardiac arrhythmia occurs, he noted.
Nearly one in five sudden cardiac deaths in young people may have a definite genetic explanation, according to scientist Vinod Scaria.
In a post on X, he identified three groups of inherited conditions linked to this risk:
An analysis of Indian genomes found variants associated with channelopathies in approximately 1% of individuals, cardiomyopathies in more than 1.5% and familial hypercholesterolaemia in about one in 150 individuals, Scaria said.
A molecular autopsy can identify genetic causes that a conventional autopsy may miss. Since many of these conditions are inherited in an autosomal dominant manner, up to half of first-degree relatives could carry the same genetic variant.
People with a family history of unexplained sudden death or inherited heart disease should seek genetic counselling.
Read More: Energy Drinks Linked To More Heart Problems In Young Adults: Study Flags Cardiac Risks
Dr Awasthy and Dr Kumar highlighted the following warning signs:
Dr Kumar said immediate cardiopulmonary resuscitation (CPR) and access to an automated external defibrillator (AED) can save a child's life if they collapse and are unresponsive or not breathing normally. He also outlined the steps teachers and bystanders should take:
For a school-age child, he advised:
Dr Kumar recommended that schools:
Credit: AI
An experimental gene therapy has shown tremendous potential in reducing the frequency of seizures in three patients with drug-resistant epilepsy.
The results have raised hopes for a new approach to treating epilepsy patients who do not respond to conventional anti-seizure medications.
All three participants experienced a reduction of more than 90% in their monthly seizure frequency after the treatment. No serious side effects were reported during the study.
The results were reported today in The New England Journal of Medicine by Yang Dai, a neurosurgeon at Xuanwu Hospital of Capital Medical University in Beijing, and his colleagues.
“It’s exciting that there’s such a dramatic effect, and that they see very few side effects,” says Matthew Walker, a neurologist at University College London who was not associated with the study.
The treatment uses a modified virus called adeno-associated virus 9 (AAV9) to deliver genetic instructions directly into the part of the brain from where seizures stem.
The virus carries a gene that instructs specific neurons, known as excitatory neurons, to produce a receptor that are sensitive to a particular medication.
Once the gene is delivered, patients take clozapine, which is an antipsychotic medication. The drug activates the receptors, reducing the activity of the neurons and helping suppress the electrical signals that cause seizures.
Researchers describe the medication as a kind of dimmer switch because it allows them to adjust the activity of the genetically modified brain cells.
Unlike conventional gene therapies, this approach gives researchers a way to regulate the treatment using medication.
The study was led by neurosurgeon Yang Dai of Xuanwu Hospital, Capital Medical University, in Beijing.
It involved three adults with drug-resistant epilepsy caused by hippocampal sclerosis, a condition in which scarring develops in the hippocampus, a brain region involved in memory and seizure activity.
All three participants had experienced epilepsy for 10 to 25 years. Despite trying at least two anti-seizure medications, their seizures still remained out of control.
They also experienced at least two seizures per month on average during the three months before entering the trial.
After gene therapy all three participants saw a reduction of more than 90% in their monthly seizure frequency.
Also read: Can ChatGPT Replace Your Doctor? Why Epilepsy Patients Should Never Alter Medication on AI Advice
Epilepsy is a neurological disorder characterised by recurrent seizures caused by abnormal electrical activity in the brain.
Anti-seizure medications can help many people control their seizures. However, some patients continue to experience seizures despite trying multiple medications.
This is known as drug-resistant epilepsy. According to the International League Against Epilepsy, it generally refers to a failure to achieve control of seizure after sufficient trials of two anti-seizure medications.
Surgery may be an option for patients with focal epilepsy if doctors can identify the brain region responsible for seizures.
The new gene therapy takes a different approach by targeting the neurons responsible for seizures.
However, experts have raised concerns about the long-term use of clozapine. High doses of the drug have been associated with cardiovascular complications and other adverse effects.
Despite the reduction in seizures, researchers have warned against interpreting the findings as proof that the treatment is effective for all people with epilepsy.
The trial involved only three participants, making it too small to probe the treatment’s long-term safety or effectiveness.
All three also had a specific form of epilepsy related to hippocampal scarring on one side of the brain. The findings cannot automatically be applied to people with other forms of epilepsy or seizures originating in different brain regions.
© $2026 Times Horizon Private Limited